A Multicenter, Randomized, Double-blind, Parallel Controlled Phase III Clinical Trial of DBRP108 in Combination With Metformin Hydrochloride in the Treatment of Type 2 Diabetes Mellitus
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Prusogliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors CSPC ZhongQi Pharmaceutical Technology
Most Recent Events
- 17 Oct 2022 Results evaluating the efficacy and safety of DBPR108 as an add-on therapy in patients with type 2 diabetes, published in the Diabetes, Obesity and Metabolism
- 30 Aug 2022 According to CSPC Pharma media release, based on the study results, company intends to submit an application for pre-NDA communication to the National Medical Products Administration of the People's Republic of China in the near future.
- 23 Jun 2021 Status changed from recruiting to completed.